Parisi Gray Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Parisi Gray Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-52	Closed	-$2K	–	498
2021 Q2	$2K	Buy	+52	New	+$1.59K	﹤0.01%	563
2019 Q2	–	Sell	-159	Closed	-$6K	–	412
2019 Q1	$6K	Hold	159	–	–	﹤0.01%	439
2018 Q4	$5K	Hold	159	–	–	﹤0.01%	477
2018 Q3	$8K	Hold	159	–	–	﹤0.01%	434
2018 Q2	$8K	Hold	159	–	–	0.01%	443
2018 Q1	$7K	Hold	159	–	–	0.01%	471
2017 Q4	$6K	Buy	+159	New	+$6.28K	﹤0.01%	525

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Parisi Gray Wealth Management's SUPN Position: Q3 2021 in Review

Parisi Gray Wealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2021, closing a stake of 52 shares — an estimated $2K sold.

Parisi Gray Wealth Management first reported a position in SUPN in Q4 2017 and held it in 7 quarters. The position peaked at $8K in Q3 2018. 223 funds tracked by Wall St. Rank hold SUPN as of Q3 2021.

Parisi Gray Wealth Management reported no remaining Supernus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Parisi Gray Wealth Management sold 52 Supernus Pharmaceuticals shares in Q3 2021, an estimated $2K.
Parisi Gray Wealth Management first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 7 quarters.
Parisi Gray Wealth Management's Supernus Pharmaceuticals position peaked at $8K in Q3 2018.
223 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2021.

Based on Parisi Gray Wealth Management's 13F filing for Q3 2021, filed 16 Nov 2021.